LifeMD Investigation Over Alleged Misleading Business Information

• LifeMD, Inc. under investigation for allegedly misleading business information. • Securities claims may have been issued to investors. • Contingency fee arrangement may be available for eligible shareholders. • Shareholders can join the class action at https://rosenlegal.com/submit-form/?case_id=43404 or call 866-767-3653.

New York, NY - Rosen Law Firm, a prominent investor rights law firm, has announced an investigation into potential securities claims on behalf of LifeMD, Inc. (NASDAQ: LFMD) shareholders. The investigation stems from allegations that LifeMD may have issued materially misleading business information to the investing public.

LifeMD reported its financial results for the second quarter of 2025 on August 5, 2025, after the market closed. In this announcement, LifeMD revised its guidance, including a reduction in expected total revenue from $268 to $275 million to $250 to $255 million. The stock price of LifeMD plummeted 44.8% on August 6, 2025, following this news.

The Rosen Law Firm is preparing a class action seeking recovery of investor losses. If you purchased LifeMD securities, you may be entitled to compensation without out-of-pocket fees or costs through a contingency fee arrangement. To join the prospective class action, visit https://rosenlegal.com/submit-form/?case_id=43404 or contact Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com.

Rosen Law Firm is known for its expertise in securities class actions and shareholder derivative litigation. The firm has a track record of success, including the largest ever securities class action settlement against a Chinese company in 2017. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs' Bar by law360.

References:
[1] https://www.marketscreener.com/news/rosen-leading-investor-counsel-encourages-lifemd-inc-investors-to-inquire-about-securities-class-ce7c51ded18df524